We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

67 hedge funds and large institutions have $256M invested in Albireo Pharma Inc in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

3% less funds holding

Funds holding: 69 → 67 (-2)

5% less capital invested

Capital invested by funds: $270M → $256M (-$13.7M)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
67
Holders Change
-2
Holders Change %
-2.9%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
26
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
+$5.33M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.27M
3
BlackRock
BlackRock
New York
+$1.96M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$1.4M
5
MWNA
Marshall Wace North America
New York
+$1.12M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.13M
3
Millennium Management
Millennium Management
New York
-$1.24M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.08M
5
EMG
Ellington Management Group
Connecticut
-$444K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$144K -$65 -2 -0%
Barclays
52
Barclays
United Kingdom
$117K +$93.6K +2,861 +429%
Bank of America
53
Bank of America
North Carolina
$114K +$62.2K +1,901 +123%
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
$110K – – –
SO
55
STRS Ohio
Ohio
$88K – – –
Citigroup
56
Citigroup
New York
$82K +$26K +794 +46%
PCM
57
Prelude Capital Management
New York
$79K +$11.7K +358 +18%
JP Morgan Chase
58
JP Morgan Chase
New York
$70K -$32.7K -1,001 -32%
Legal & General Group
59
Legal & General Group
United Kingdom
$45K – – –
TDC
60
Thompson Davis & Co
Virginia
$42K -$4.09K -125 -9%
AIP
61
Ameritas Investment Partners
Nebraska
$23K – – –
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
$9.82K -$65 -2 -0.7%
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$9K +$3.14K +96 +54%
PMFA
64
Plante Moran Financial Advisors
Michigan
$2K – – –
PFGIA
65
Patriot Financial Group Insurance Agency
Massachusetts
$1K +$818 +25 New
Two Sigma Investments
66
Two Sigma Investments
New York
– -$1.08M -30,443 Closed
EMG
67
Ellington Management Group
Connecticut
– -$444K -12,500 Closed
DS
68
DRW Securities
Illinois
– -$320K -9,000 Closed
Manulife (Manufacturers Life Insurance)
69
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$269K -7,572 Closed
Goldman Sachs
70
Goldman Sachs
New York
– -$214K -6,025 Closed
TRCT
71
Tower Research Capital (TRC)
New York
– -$31K -949 -99%
PIA
72
Piedmont Investment Advisors
North Carolina
– -$6K -158 Closed
VIA
73
Vantage Investment Advisors
Pennsylvania
– -$4K -100 Closed
1 2
3

ALBO Hedge Fund Activity: Q3 2018 in Review

67 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2018, worth a combined $256M — down 5.1% from $270M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ALBO and 5 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 26 added.

The largest buyer was Prosight Management, opening a new position worth an estimated $5.33M. The largest seller was Fidelity Investments, cutting an estimated $4.8M.

  • 67 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2018, down from 69 in Q2 2018.
  • Funds reported $256M of Albireo Pharma Inc stock for Q3 2018, down 5.1% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q3 2018 and 7 closed out, a net change of -2 holders.
  • The largest Albireo Pharma Inc buyer in Q3 2018 was Prosight Management, an estimated $5.33M added.
  • The largest Albireo Pharma Inc seller in Q3 2018 was Fidelity Investments, an estimated $4.8M sold.

Based on aggregated 13F filings for Q3 2018.